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Abstract
Introduction: Patients with septic shock require fluid, but the optimum amount is unknown. Therefore we
assessed patient characteristics and outcome associated with fluid volume in unselected patients with septic shock
including those with three days of shock.
Methods: We conducted a prospective, multicenter, observational study of all adult patients with septic shock
during a 3-month study period at six general ICUs: three in university hospitals and three in regional hospitals.
After day 1 and 3 of shock, patients were divided into two groups according to the overall median fluid volumes.
Characteristics between these groups were compared using non-parametric and Chi-square statistics.
Results: The 164 included patients received median 4.0 l (IQR 2.3-6.3) of fluid during the first day of septic shock.
Patients receiving higher volumes (> 4.0 l) on day 1 had higher p-lactate (3.4 (2.2-5.5) vs. 2.0 (1.6-3.0) mmol l-1, P <
0.0001) compared to those receiving lower volumes. In contrast simplified acute physiology score (SAPS) II (54 (45-
64) vs. 54 (45-67), P = 0.73), sequential organ failure assessment (SOFA) score (11 (9-13) vs. 11 (9-13), P = 0.78) and
90-day mortality (48 vs. 53%, P = 0.27) did not differ between groups. The 95 patients who still had shock on day 3
had received 7.5 l (4.3 - 10.8) of fluid by the end of day 3. Patients receiving higher volumes (> 7.5 l) had higher p-
lactate (2.6 (1.7-3.4) vs. 1.9 (1.6-2.4) mmol l-1, P < 0.01) on day 3 and lower 90-day mortality (40 vs. 62%, P = 0.03)
than those receiving lower volumes in spite of comparable admission SAPS II (53 (46-67) vs. 55 (49-62), P = 0.47)
and SOFA scores on day 3 (10 (8-13) vs. 11 (10-14), P = 0.33).
Conclusions: In this cohort of unselected ICU patients with septic shock, initial fluid volume was not associated
with mortality. In patients with shock for three days or more, higher fluid volumes including crystalloids, colloids
and blood products were associated with reduced mortality.
Introduction
Sepsis is characterized by inflammation-induced
endothelial dysfunction leading to vascular leakage and
vasodilatation. Ultimately, this results in relative and
absolute hypovolemia, organ hypoperfusion, and septic
shock. If shock persists, the result is progressive multiple
organ failure and high mortality [1].
The circulatory treatment of patients with septic shock
is to administer intravenous (IV) fluids and inotrope/
vasopressor drugs to optimize cardiac preload and organ
perfusion [2]. It is currently unknown whether a strategy
using higher or lower fluid volume is better. The Surviv-
ing Sepsis Campaign (SSC) recommends goal-directed
optimization in the first 6 hours followed by fluid chal-
lenges in case of persistent hypoperfusion. The former is
based on one relatively small, single-center, randomized
clinical trial (RCT) [3] and the latter on expert opinion.
Even though these approaches may be physiologically
rational, the recommendations illustrate the low level of
evidence for fluid volume in septic shock.
Recent cohort studies [4-6] indicated that positive
fluid balance was associated with increased mortality.
However, neither of these studies was done in unse-
lected patients with septic shock, who may have the
highest benefit of fluid therapy. If fluids benefit these
patients, this may be better captured by volumes of IV
* Correspondence: anders.perner@rh.regionh.dk
Department of Intensive Care, Copenhagen University Hospital,
Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark
Smith and Perner Critical Care 2012, 16:R76
http://ccforum.com/content/16/3/R76
© 2012 Smith et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
fluid given instead of by fluid balance, which is affected
by fluid output.
Therefore, our aim was to describe patient characteris-
tics and mortality in a cohort of unselected patients with
septic shock treated with higher versus lower volumes of
IV fluids during shock. As patients with persisting septic
shock may present a subgroup needing higher volumes
of fluid, we performed subgroup analyses of those
patients remaining in shock for 3 days or more.
Materials and methods
This was a prospective, cohort study of consecutive
patients with septic shock in the intensive care unit
(ICU). Patients were included from the general ICUs at
Rigshospitalet and Herlev, Glostrup, Gentofte, Køge, and
Hillerød hospitals (Denmark) during a 3-month study
period. Three of these are university hospitals and three
are regional hospitals. The 3-month study period varied
between units, but all were within the period of 1 Feb-
ruary to 30 June 2009. The staff at the units was una-
ware of the study.
All patients with septic shock in the study period were
included. Septic shock was defined as (a) documented
or suspected infection; (b) two of the following: tem-
perature of less than 36°C or more than 38°C, leukocyte
count of less than 4 × 109/L or more than 12 × 109/L,
respiratory frequency of more than 20 breaths per min-
ute or mechanical ventilation, or heart rate of more
than 90 beats per minute; (c) signs of organ failure -
sequential organ failure assessment (SOFA) scores of 2
or more in the cerebral, kidney, liver, lung, or coagula-
tion component - or plasma lactate of more than 2
mmol/L; and (d) need of vasopressor infusion to main-
tain systolic blood pressure of more than 90 mm Hg
after initial fluid resuscitation [7]. The Ethics Committee
of the Capital Region and the Danish Data Protection
Agency and the National Board of Health approved the
study. Consent was waived because all interventions and
measurements were clinically indicated.
Data acquisition
Data were registered from the time septic shock was
diagnosed in the ICU and continued as long as the
patient received vasopressor or inotropic therapy, so
that any day with one of these therapies represented a
shock day. For patients who had shock on ICU admit-
tance, data from the pre-ICU period were not registered,
as we previously found low quality of such data in a
comparable cohort [8].
The following general characteristics were recorded:
gender, age, if emergency surgery had been performed,
site of infection, simplified acute physiology score II
(SAPS II) based on observations during the first 24
hours in the ICU, and SOFA scores on days of shock.
SAPS II and SOFA scores of patients who stayed in the
ICU less than 24 hours were determined on the basis of
the data available from the time they did stay in the
ICU. The mortality 90 days after inclusion was regis-
tered from the national Danish hospital administration
system (GS Open) by using national identification num-
bers. This ensured full mortality follow-up of Danish
citizens. Two patients were non-Danish citizens and
were alive at hospital discharge and therefore counted
as survivors in the 90-day mortality analysis.
The following interventions were recorded every day
during shock: the type and volume of administered fluid,
including crystalloids (isotonic NaCl, Ringer’s lactate or
acetate, other electrolyte solutions, or isotonic glucose);
colloids (albumin, hydroxyethyl starch (HES), or dextran;
gelatin was not used in the present cohort); blood pro-
ducts (red blood cells (RBCs), fresh frozen plasma, or pla-
telet concentrate; blood products were included because
data indicate that these are used for resuscitation in
Scandinavian ICUs [9,10]); nutrition given (any nutri-
tional product containing glucose of greater than 5%,
amino acids, or lipids); use of corticosteroids, invasive
ventilation, or renal replacement therapy; and type and
maximum dose of infused inotrope/vasopressor drugs.
Dopamine doses were converted into comparable doses
of norepinephrine so that 1 μg/kg per minute dopamine
equaled 0.01 μg/kg per minute norepinephrine [11]. The
converted dose of dopamine was added to any norepi-
nephrine dose to give the maximum vasopressor dose.
None of the patients received vasopressin.
The following monitoring characteristics were
recorded every day during shock: highest values of
plasma lactate and lowest central venous oxygen satura-
tion (ScvO2) in the superior caval vein and any use of
any device for cardiac output measurement. All data
were collected on paper case report forms by a single
investigator (SHS) and entered into an Excel (Microsoft
Corporation, Redmond, WA, USA) data sheet.
Statistics
Patients were divided into two groups according to the
full cohort’s median IV fluid volume administered in the
first 24 hours of shock. Volumes of fluid given as nutri-
tion were not included, because the purpose of the
study was to assess the effects of IV fluid treatment.
Patients who still had shock on day 3 after inclusion
were divided into two groups according to the median
fluid volume administered in the first 3 days of shock.
This way of comparing higher versus lower fluid volume
was previously done for the first 6 and 24 hours in
patients with severe sepsis and septic shock, respectively
[8,12]. The 3-day time point was chosen because it was
used in the SOAP (Sepsis Occurrence in Acutely Ill
Patients) cohort [4].
Smith and Perner Critical Care 2012, 16:R76
http://ccforum.com/content/16/3/R76
Page 2 of 7
Data were expressed as median and interquartile range
(IQR) for continuous variables and as number of patients
and percentage for categorical variables. Mann-Whitney
U test was used to compare unpaired continuous data
because the fluid data were not normally distributed, and
chi-squared test was used for categorical data. P values of
less than 0.05 were used as the level of statistical signifi-
cance, and GraphPad Prism version 5.04 (GraphPad Soft-
ware, La Jolla, CA, USA) was used to analyze data.
Results
A total of 164 ICU patients with septic shock were
included; their characteristics are given in Table 1. Of
the 164 included, 24 had died and 45 had shock resolu-
tion in the first 2 days after inclusion. Thus, 95 patients
still had shock on the third day after inclusion. There
were no differences between these 95 patients in admis-
sion SAPS II (54, IQR 48 to 63 versus 52, IQR 42 to 67,
P = 0.54), SOFA score on day 1 (11, IQR 9 to 13 versus
10, IQR 8 to 13, P = 0.30), and 90-day mortality (52%
versus 49%, P = 0.77) and the 69 patients who died or
had shock resolution in the first 2 days after inclusion.
Monitoring characteristics
All patients but one had plasma lactate measured on the
first day of shock (median of 8 assessments per patient,
IQR 6 to 10), and all patients in shock on the third day
had lactate measured on day 3 (8 assessments per
patient, IQR 6 to 9). One hundred twenty-five patients
had ScvO2 measured on the first day of shock (2 assess-
ments per patient, IQR 1 to 3), and 65 patients of the
95 still in shock on day 3 had ScvO2 measured (1
assessment per patient, IQR 1 to 2). No patients had a
catheter for continuous ScvO2 measurements. On the
first day of shock, 16 of the 164 patients had cardiac
output measured; on the third day of shock, 19 of the
95 patients had cardiac output measured.
Fluids given in the ICU on the first day of shock
The 164 included patients received a median of 4.0 L
(IQR 2.3 to 6.3) of IV fluid in the ICU during the first
day of septic shock. The patients receiving higher
volumes of fluid (> 4.0 L) received more crystalloids,
colloids, and blood products (Tables 2 and 3) compared
with those receiving lower fluid volumes. The higher-
volume group had a higher maximum value of plasma
lactate and a tendency to higher maximum vasopressor
dose compared with the lower-volume group (Table 2).
In contrast, there were no differences between the two
fluid volume groups in admission SAPS II, SOFA score
on day 1, minimum ScvO2, and 90-day mortality (Table
2). Comparable results were obtained if fluid given as
nutrition was added to the fluid volumes (data not
shown).
Nutrition given in the ICU on the first day of shock
A median of 0.5 L (IQR 0.2 to 1.1) of nutrition was
given on the first day of shock, and the higher-fluid
volume group received less nutritional volume than the
lower-fluid group (0.4 L, IQR 0.1 to 0.9 versus 0.8 L,
IQR 0.2 to 1.3, P = 0.0009).
Cumulative urinary output and fluid balance in the ICU
on the first day of shock
The cumulative urinary output was 1.3 L (IQR 0.4 to
2.4) by the end of the first day of shock without a differ-
ence between the higher- and lower-fluid volume groups
(1.2 L, IQR 0.4 to 2.1 versus 1.7 L, IQR 0.4 to 2.6, P =
0.46). The cumulative fluid balance was 3.4 L (IQR 1.5
to 5.6) by the end of the first day. The patients receiving
higher volumes of fluid had a higher cumulative fluid
balance in the first day of shock compared with those
receiving lower fluid volumes (5.6 L, IQR 4.1 to 7.3 ver-
sus 1.9 L, IQR 0.5 to 2.9, P < 0.0001).
Fluids given in the ICU in the first 3 days of shock
The 95 patients who still had shock on the third day
after inclusion had received a median of 7.5 L (IQR 4.3
to 10.8) of IV fluid by the end of the third shock day.
The patients receiving higher fluid volumes (> 7.5 L) in
Table 1 Characteristics and selected therapies during
shock in 164 consecutive intensive care unit patients
with septic shock
Characteristics n = 164
Males, number (percentage) 93 (57)
Age in years, median (IQR) 66 (59-74)
SAPS II, median (IQR) 54 (46-67)
Emergency surgery, number (percentage) 61 (37)
Estimated weight in kilograms on admission, median (IQR) 78 (65-93)
Focus of infection, number (percentage)
Pulmonary 66 (40)
Gastrointestinal 46 (28)
Soft tissue 15 (9)
Urinary tract 9 (5)
Intravenous catheter 4 (2)
Other 5 (3)
Unclear 19 (12)
Shock duration in daysa, median (IQR) 3 (2-5)
Therapies during septic shock, number (percentage)
Invasive ventilation 147 (90)
Renal replacement therapy 65 (40)
Corticosteroids 79 (48)
Mortality, number (percentage)
Day 30 65 (40)
Day 90 83 (51)
aThe total shock duration in the intensive care unit. IQR, interquartile range;
SAPS II, simplified acute physiology score II.
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the first 3 days of shock received more crystalloids, col-
loids, and blood products compared with those receiving
lower fluid volumes and had a higher maximum plasma
lactate on day 3 (Tables 2 and 3). The two groups had
comparable admission SAPS II and SOFA scores, maxi-
mum vasopressor dose, and minimum ScvO2 on day 3
(Table 2), but the higher-fluid volume group had a
lower 90-day mortality than the lower-fluid volume
group (Table 2). Comparable results were obtained if
fluid given as nutrition was added to the fluid volumes
(data not shown).
Nutrition given in the ICU in the first 3 days of shock
A median of 3.2 L (IQR 2.3 to 4.2) of nutrition was
given on the first 3 days of shock, and the higher-fluid
volume group received a significantly lower volume of
Table 2 Characteristics dependent on fluid volume in the ICU in the first day and the first 3 days of shock in
consecutive ICU patients with septic shock
Day 1, n = 164 Day 1-3, n = 95
High fluid volume
(> 4.0 L), n = 82
Low fluid volume
(< 4.0 L), n = 82
P value High fluid volume
(> 7.5 L), n = 47
Low fluid volume
(< 7.5 L), n = 48
P value
Total fluid volume, liters 6.3 (5.1-8.2) 2.3 (1.1-3.0) < 0.0001 10.9 (8.7-13.3) 4.3 (3.0-5.7) < 0.0001
Crystalloids, liters 3.9 (3.0-6.0) 2.0 (1.0-2.3), n = 59 < 0.0001 7.0 (4.5-9.8) 2.8 (0.5-4.3), n = 40 < 0.0001
Colloids, liters 1.1 (0.6-1.6), n = 72 0.5 (0.4-1.0), n = 64 < 0.0001 2.1 (1.0-2.5), n = 46 1.0 (0.5-1.5), n = 40 < 0.0001
Blood products, liters 1.2 (0.6-2.8), n = 53 0.5 (0.2-0.9), n = 34 < 0.0001 2.6 (1.1-4.3), n = 41 1.1 (0.5-1.9), n = 32 < 0.001
SAPS II on admission 54 (45-64) 54 (45-67) 0.73 53 (46-67) 55 (49-62) 0.47
SOFA scorea 11 (9-13) 11 (9-13) 0.99 10 (8-13) 11 (10-14) 0.33
Maximum p-lactate in mmol/La 3.4 (2.2-5.5) 2.0 (1.6-3.2), n = 81 < 0.0001 2.6 (1.7-3.4) 1.9 (1.6-2.4) < 0.01
Minimum ScvO2, percentage
a 70 (63-77), n = 68 73 (66-78), n = 57 0.26 74 (66-80), n = 34 74 (68-79), n = 31 0.35
Maximum vasopressor in μg/kg
per minutea
0.25 (0.12-0.43) 0.18 (0.10-0.32) 0.07 0.16 (0.10-0.24) 0.15 (0.08-0.22) 0.57
Renal replacement therapy,
number (percentage)
32 (39) 32 (39) 1.00 18 (38) 16 (33) 0.61
90-day mortality, number
(percentage)
38 (46) 45 (55) 0.27 19 (40) 29 (62) 0.03
Values are presented as median (interquartile range) or as number of patients (percentage). Group comparisons were done by Mann-Whitney U test including all
patients in the groups (82 versus 82 and 47 versus 48 patients) or chi-squared test by relevance. The number (n) is given in the specific cell that applies; for all
other variables, n was as given in the top of the column. aOn days 1 and 3, respectively. ICU, intensive care unit; SAPS II, simplified acute physiology score II,
ScvO2, central venous oxygen saturation, SOFA, sequential organ failure assessment.
Table 3 Details on fluids dependent on total fluid volume in the first day in the ICU and the first 3 days of shock in
consecutive ICU patients with septic shock
Day 1, n = 164 Day 1-3, n = 95
Crystalloids High fluid volume
(> 4.0 L, n = 82)
Low fluid volume
(< 4.0 L, n = 82)
P value High fluid volume
(> 7.5 L, n = 47)
Low fluid volume
(< 7.5 L, n = 48)
P value
0.9% NaCl, liters 2.3 (1.0-4.0), n = 60 1.0 (0.6-1.6), n = 28 < 0.0001 3.0 (1.1-6.0), n = 35 1.0 (0.9-2.0), n = 19 < 0.01
Ringer solutions, liters 2.5 (2.0-4.0), n = 49 1.5 (1.0-2.0), n = 31 < 0.0001 3.1 (2.0-5.6), n = 34 2.0 (1.0-3.0), n = 29 < 0.01
Other electrolyte solutions, liters 1.0 (0.5-1.4), n = 32 1.0 (0.6-1.0), n = 22 0.48 1.5 (0.9-1.9), n = 29 1.0 (0.6-1.2), n = 18 0.14
Isotonic glucose, liters 1.0 (0.5-1.0), n = 16 0.5 (0.5-0.5), n = 4 0.02 1.0 (0.6-2.7), n = 14 0.5 (0.1-1.0), n = 3 0.10
Colloids, liters
5% albumin 0.5 (0.4-1.0), n = 22 0.5 (0.3-0.8), n = 26 0.72 0.8 (0.5-1.5), n = 24 0.5 (0.4-1.0), n = 21 0.25
20% albumin 0.2 (0.1-0.3), n = 23 0.2 (0.2-0.3), n = 21 0.78 0.3 (0.1-0.4), n = 19 0.2 (0.2-0.4), n = 20 0.53
6% HES 130/0.4 1.0 (0.5-1.5), n = 52 0.5 (0.5-1.0), n = 23 < 0.0001 1.5 (1.0-2.0), n = 35 1.0 (0.5-1.5), n = 14 < 0.0001
6% dextran 70 1.0 (0.9-1.0), n = 10 0.8 (0.5-1.0), n = 9 0.76 1.0 (0.5-1.2), n = 12 0.6 (0.5-1.0), n = 12 0.90
Blood products, liters
Red blood cells 0.7 (0.5-1.2), n = 48 0.3 (0.2-0.5), n = 22 < 0.0001 1.0 (0.6-1.8), n = 39 0.5 (0.3-0.8), n = 20 < 0.0001
Fresh frozen plasma 0.6 (0.4-1.3), n = 38 0.5 (0.5-0.6), n = 13 < 0.0001 1.4 (0.9-1.8), n = 33 1.1 (0.5-1.1), n = 17 < 0.0001
Platelet concentrate 0.7 (0.4-1.3), n = 17 0.7 (0.4-1.1), n = 7 0.03 0.7 (0.6-1.4), n = 20 1.2 (0.7-1.6), n = 8 0.02a
Values are presented as median (interquartile range) of the number given in the specific cell; this number denotes the number of patients given the specific
solution. Group comparisons were done by Mann-Whitney U test including all patients in the groups (82 versus 82 and 47 versus 48 patients). aThe higher-
volume group received significantly more platelets (P = 0.02) because more patients received platelets compared with the lower-volume group (20 versus 8
patients). HES, hydroxyethyl starch (molecular weight/substitution degree).
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nutrition compared with the lower-fluid volume group
(2.9 L, IQR 2.1 to 3.9 versus 3.4 L, IQR 2.6 to 4.4, P =
0.04).
Cumulative urinary output and fluid balance in the ICU in
the first 3 days of shock
In the 95 patients who still had shock on the third day,
the cumulative urinary output was 5.7 L (IQR 1.8 to
8.7) by the end of that third day without a difference
between the higher- and lower-fluid volume groups (5.6
L, IQR 1.9 to 8.7 versus 5.9 L, IQR 0.7 to 9.1, P = 0.67).
The cumulative fluid balance was 5.4 L (IQR 2.7 to 9.4)
by the end of that third day. The patients receiving
higher volumes of fluid had a higher cumulative fluid
balance in the first 3 days of shock compared with those
receiving lower fluid volumes (9.2 L, IQR 5.3 to 13.6
versus 2.9 L, IQR 0.9 to 5.4, P < 0.0001).
Discussion
The main finding of this study was that, in comparison
with patients receiving lower volumes of fluid, those
receiving higher initial fluid volumes had higher lactate
levels but the same 90-day mortality. In contrast, the
combination of higher volumes of crystalloids, colloids,
and blood products was associated with lower mortality
in the subgroup of patients with shock lasting 3 days or
more. This was surprising because analyses from the
SOAP and VASST (Vasopressin and Septic Shock Trial)
cohorts have shown the opposite result.
In the SOAP study [4], positive fluid balance on the
third day after the onset of infection was associated with
increased ICU mortality in the subgroup of patient with
sepsis, among whom 40% had septic shock. Recent
results from VASST [5] also indicated that a positive
fluid balance at both 12 hours and day 4 was associated
with increased 28-day mortality. The VASST cohort was
highly selected as only 13% of screened patients were
included. In neither of these two studies was there infor-
mation on the types of fluid given. Also, multivariate
analyses were used to show the effect of fluid balance
on outcome in the VASST and SOAP cohorts. Such
analyses may be difficult to construct for complex inter-
ventions in complex settings. The challenges are con-
founding by indication, time dependency, and repeated
exposure of the intervention and competing risks. In
contrast, we used unadjusted analyses in the present
study. Some of the above potential biases also hamper
the interpretation of our results. In particular, the day 3
cohort may be subjected to bias because these patients
survived to day 3 but still had shock. The systematic
exclusion of the most sick (those who died) and the
least sick (those who had shock resolution) may have
introduced selection biases, which are difficult to assess.
On the other hand, the persisting shock group had
admission SAPS II, SOFA score on day 1, and 90-day
mortality that were comparable to those of the group of
dropouts.
Also, a retrospective cohort study by Murphy and col-
leagues [6] assessed potential effects of fluid volumes.
The study was of patients with septic shock, but again
the cohort was selected, as acute lung injury was an
inclusion criterion and there were several exclusion cri-
teria. This study indicated that higher initial IV fluid
volumes were associated with lower mortality if negative
fluid balance was obtained on two consecutive days
within the first 7 days of shock [6].
The findings in the present study are partly supported
by those of studies of fluid resuscitation in the first 6
hours of patients with severe sepsis in Canadian ICUs
[12] and in the first 24 hours of patients with septic
shock in Scandinavian ICUs [8]. Neither of these studies
found outcome to be associated with initial volumes of
IV fluids.
Direct comparison between the previous studies and
our study is difficult, because we focused on IV fluid
volume given to unselected patients with septic shock,
allowing detailed analyses of those with persistent shock.
Also, we divided patients into groups receiving higher
and lower volumes of fluids. Hereby, we observed that
patients receiving higher fluid volumes had higher lac-
tate levels, indicating hypoperfusion and the need for
intervention. This may explain the potential benefit of
fluid in the higher-volume group with persisting septic
shock. In any case, clinicians should interpret results of
cohort studies with caution before making inferences on
treatment. But until we have data from RCTs on fluid
volume in septic shock, patients with persisting shock
and hypoperfusion should be carefully assessed for
hypovolemia and fluid challenged as recommended in
the SSC guidelines [2].
Colloid use
The composition of resuscitation fluids for sepsis is con-
troversial. In particular, the use of colloid is a matter of
debate [13]. In the present study, the administration of
colloids (in particular, HES 130/0.4) was not associated
with increased mortality or use of dialysis. This con-
trasts with results from a recent before-and-after study
in patients with severe sepsis in a single ICU [13],
where use of HES 130/0.4 was associated with kidney
injury and a tendency to increased use of dialysis. How-
ever, the doses of HES 130/0.4 appeared to be higher in
that study (median of 46 mL/kg during ICU stay) com-
pared with ours (13 mL/kg in the first day of shock and
19 mL/kg for those who still had shock on day 3).
Neither of the two large RCTs comparing colloids with
crystalloids showed significant changes in mortality
[14,15]. These divergent results underline the need for
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large RCTs on the efficacy and safety of colloid treat-
ment in patients with sepsis, in particular 6% HES 130/
0.4, as this solution is largely unstudied in these
patients. Two large RCTs randomly assigning hypovole-
mic ICU patients to 6% HES 130/0.4 versus crystalloids
are ongoing [16,17].
Blood product use
The use of blood products in the resuscitation of
patients with sepsis is controversial, but in the present
study these were not associated with worse outcome. In
contrast, the patients who had persisting septic shock
and who also received higher volumes of RBCs, plasma,
and platelets had better survival. There are hardly any
data on the efficacy and safety of plasma and platelet
therapy in patients with sepsis, but the two trials ran-
domly assigning patients with sepsis to different RBC
transfusion strategies have shown divergent results. Riv-
ers and colleagues [3] found increased survival with a
complex early goal-directed protocol including RBC
transfusion if hypoperfusion persisted. On the other
hand, the TRICC (Transfusion Requirements in Critical
Care) trial found a tendency toward increased mortality
with liberal RBC transfusion in the subgroup of patients
with sepsis [18], but these were included only after
resuscitation. Non-leukocyte-depleted RBCs were used
in the TRICC trial, whereas Danish hospitals use pre-
storage leukocyte-depleted RBCs suspended in saline-
adenine-glucose-mannitol (SAGM). Again, large RCTs
are needed to test the efficacy and safety of RBCs, fresh
frozen plasma, and platelet concentrates in patients with
sepsis.
Strengths and weaknesses
The strengths of this study include prospective inclusion
of consecutive patients at multiple university and non-
university ICUs using a well-defined definition of septic
shock, detailed registration of fluids given, and follow-
up using national identification numbers, which ensured
close to full follow-up.
There are clear limitations to this study. First of all,
the descriptive design precludes strong conclusions
regarding effects of fluid volume in patients with sepsis.
Also, data on co-morbidities, pre-ICU interventions,
some co-interventions, and subsequent interventions
after the shock period were not registered. The specific
timing and rate of fluid infusion were not assessed, nor
were the specific therapy triggers and goals that clini-
cians used. Also, we did not register if central venous
pressure was assessed and registered, because we had
previously shown that this marker of preload is used
less during resuscitation of patients with septic shock in
Danish ICUs [8]. On the other hand, the evidence to
support the use of any specific trigger and goal for fluid
resuscitation of ICU patients with septic shock is weak,
in particular beyond the first 6 hours [2].
Conclusions
In this cohort of unselected patients with septic shock,
initial fluid volume was not associated with mortality. In
patients with shock for 3 days or more, higher fluid
volumes including crystalloids, colloids, and blood pro-
ducts were associated with reduced mortality. This con-
trasts with results from other cohort studies,
underlining the need for RCTs on fluid volume in septic
shock.
Key messages
• Septic shock patients who received higher intrave-
nous (IV) fluid volumes, including crystalloids, col-
loids, and blood products, on day 1 had higher p-
lactate on day 1.
• Mortality was independent of IV fluid volume on
day 1 of septic shock.
• Persisting-shock patients who received higher
cumulated IV fluid volumes, including crystalloids,
colloids, and blood products, at the end of day 3 had
higher p-lactate on day 3.
• In patients with persisting shock, mortality was
lower in the group receiving higher IV fluid volume
than in those receiving lower fluid volume.
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